A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Conditions
Relapsed AL Amyloidosis · Refractory AL Amyloidosis · Light Chain Amyloidosis · Amyloidosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Research Site, Phoenix, Arizona, United States
Research Site, San Francisco, California, United States
Research Site, Tampa, Florida, United States
Research Site, Boston, Massachusetts, United States
Research Site, Detroit, Michigan, United States
Research Site, Rochester, Minnesota, United States
Research Site, St Louis, Missouri, United States
Research Site, New York, New York, United States
Research Site, New York, New York, United States
Research Site, New York, New York, United States
Research Site, Cleveland, Ohio, United States
Research Site, Nashville, Tennessee, United States
Research Site, Calgary, Alberta, Canada
Research Site, Calgary, Alberta, Canada
Research Site, Toronto, Ontario, Canada
Research Site, Toronto, Ontario, Canada
Research Site, London, United Kingdom
Research Site, London, United Kingdom